The present study was aimed to scientifically demonstrate the anti-hypertensive action of Venthamarai chooranam (VMC) in renal hypertensive rats. Two Kidney One Clip (2K1C) Goldblatt model was adopted to induce hypertension in rats. Male Sprague Dawley rats (270–320 g) were randomized into sham (n = 6), vehicle-treated 2K1C (n = 9) and VMC-treated 2K1C (400 mg/kg, p.o; n = 8) and monitored for nine weeks. Systolic blood pressure (SBP), plasma nitrate/nitrite, carotid endothelial nitric oxide synthetase (eNOS), renal angiotensin type 1 receptor (AT1R), angiotensin type 2 receptor (AT2R), TNFα, IL-6, thioredoxin 1 (TRX1), and thioredoxin reductase 1 (TRXR1) mRNA expressions were studied. VMC upregulated eNOS expression which in turn improved plasma nitric oxide and decreased SBP in hypertensive rats. It down-regulated AT1R and simultaneously upregulated AT2R expression in comparison to vehicle-treated 2K1C rats. Further, renal TNFα and IL-6 expressions were down-regulated while TRX1 and TRXR1 were upregulated by VMC. VMC potentially interacts with renin-angiotensin components and endothelial functions, and thereby exerts its antihypertensive action. This is the first study to demonstrate the mechanism of anti-hypertensive action of VMC in an animal model of renovascular hypertension.
WongPCHartSDZaspelAMChiuATArdeckyRJSmithRDTimmermansPB. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther1990; 255: 584–92.
2.
TimmermansPBWongPCChiuATHerblinWFBenfieldP CariniDJLeeRJWexlerRRSayeJASmithRD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev1993; 45: 205–51.
3.
FerreriNREscalanteBAZhaoYAnSJMcGiffJC. Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol1998; 274: F148–55.
4.
WolfGSchneiderAWenzelUHelmchenUStahlRA. Regulation of glomerular TGF-beta expression in the contralateral kidney of two-kidney, one-clip hypertensive rats. J Am Soc Nephrol1998; 9: 763–72.
5.
ChabrashviliTKitiyakaraCBlauJKarberAAslamSWelchWJWilcoxCS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regulat Integr Compar Physiol2003; 285: R117–24.
6.
HiyoshiHYayamaKTakanoMOkamotoH. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension2004; 43: 1258–63.
7.
WuLIwaiMNakagamiHLiZChenRSuzukiJAkishitaMde GasparoMHoriuchiM. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation2001; 104: 2716–21.
PreobrazhenskiiDVSidorenkoBA. Adverse effects of angiotensin II type 1 receptor blockers. Kardiologiia2002; 42: 88–94.
11.
MoncadaSHiggsEA. Nitric oxide and the vascular endothelium. Handbook of experimental pharmacology, Heidelberg: Springer Verlag, 2006 (176 Pt 1), pp. 213–54. .
12.
MarkhamAGoaKL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs1997; 54: 299–311.
13.
AchenbachTWeinheimerOBrochhausenCHollemannDBaumbachBScholzADuberC. Accuracy of automatic airway morphometry in computed tomography-correlation of radiological-pathological findings. Eur J Radiol2012; 81: 183–8.
14.
OECD. OECD guidelines for testing of chemicals, Paris: Organisation for Economic Co-operation and Development, 1981.
15.
GoldblattHLynchJHanzalRFSummervilleWW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med1934; 59: 347–79.
16.
HallLLBicknellGRPrimroseLPringleJHShawJAFurnessPN. Reproducibility in the quantification of mRNA levels by RT-PCR-ELISA and RT competitive-PCR-ELISA. BioTechniques1998; 24: 652–8.
17.
GreenLCTannenbaumSRFoxJG. Nitrate in human and canine milk. New Engl J Med1982; 306: 1367–8.
18.
MartinJKrumH. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Pharmacol Res: Official J Italian Pharmacol Soc2002; 46: 203–12.
19.
FernsGARainesEWSprugelKHMotaniASReidyMARossR. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science1991; 253: 1129–32.
20.
De PaolisPPorcelliniAGiganteBGilibertiRLombardiASavoiaCRubattuSVolpeM. Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells. J Hypertens1999; 17: 1873–7.
21.
JinXQFukudaNSuJZLaiYMSuzukiRTahiraYTakagiHIkedaYKanmatsuseKMiyazakiH. Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. Hypertens2002; 39: 1021–7.
22.
ParvingHHBrennerBMCooperMEde ZeeuwDKeaneWFMitchWERemuzziGSnapinnSMZhangZShahinfarS. Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy. Ugeskrift for laeger2001; 163: 5514–9.
23.
SiragyHMInagamiTCareyRM. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regulat Integr Compar Physiol2007; 293: R1461–7.
24.
ForstermannUMunzelT. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation2006; 113: 1708–14.
25.
ForstermannU. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nature clinical practice. Cardiovasc Med2008; 5: 338–49.
26.
EliasADKumarPHerndonJ3rdSkarinATSugarbakerDJGreenMR. Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. Clin Lung Cancer2002; 4: 95–103.
27.
AzzolinaABongiovanniALampiasiN. Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochim Biophys Acta2003; 1643: 75–83.
28.
TanitoMNakamuraHKwonYWTerataniAMasutaniHShiojiKKishimotoCOhiraAHorieRYodoiJ. Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxidants Redox Signal2004; 6: 89–97.
29.
WarnholtzANickenigGSchulzEMacharzinaRBrasenJHSkatchkovMHeitzerTStaschJPGriendlingKKHarrisonDGBohmMMeinertzTMunzelT. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation1999; 99: 2027–33.
30.
SchiefferBBunteCWitteJHoeperKBogerRHSchwedhelmEDrexlerH. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am College Cardiol2004; 44: 362–8.
31.
Majewska-WierzbickaMCzeczotH. Flavonoids in the prevention and treatment of cardiovascular diseases. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego2012; 32: 50–4.
32.
MulvihillEEHuffMW. Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can J Cardiol2010; 26: 17A–21A.
33.
ScholzEPZitronEKatusHAKarleCA. Cardiovascular ion channels as a molecular target of flavonoids. Cardiovasc Ther2010; 28: e46–52.
34.
GrassiDDesideriGCroceGTibertiSAggioAFerriC. Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des2009; 15: 1072–84.
35.
LorenzMWesslerSFollmannEMichaelisWDusterhoftTBaumannGStanglKStanglV. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem2004; 279: 6190–5.
36.
AnterEThomasSRSchulzEShapiraOMVitaJAKeaneyJF,Jr. Activation of endothelial nitric-oxide synthase by the p38 MAPK in response to black tea polyphenols. J Biol Chem2004; 279: 46637–43.
37.
AnterEChenKShapiraOMKarasRHKeaneyJF,Jr. p38 mitogen-activated protein kinase activates eNOS in endothelial cells by an estrogen receptor alpha-dependent pathway in response to black tea polyphenols. Circulation Res2005; 96: 1072–8.
